Pfizer’s Obesity Biotech Win Signals Regulatory Shift
Pfizer has won early antitrust approval for its acquisition of obesity biotech Metsera, beating back a $9 billion unsolicited bid from Novo Nordisk. The FTC’s move during a government shutdown signals regulatory priorities in the heated weight-loss drug competition.